Literature DB >> 28691797

Caught before Released: Structural Mapping of the Reaction Trajectory for the Sofosbuvir Activating Enzyme, Human Histidine Triad Nucleotide Binding Protein 1 (hHint1).

Rachit Shah1, Kimberly M Maize1, Xin Zhou1, Barry C Finzel1, Carston R Wagner1.   

Abstract

Human histidine triad nucleotide binding protein 1 (hHint1) is classified as an efficient nucleoside phosphoramidase and acyl-adenosine monophosphate hydrolase. Human Hint1 has been shown to be essential for the metabolic activation of nucleotide antiviral pronucleotides (i.e., proTides), such as the FDA approved hepatitis C drug, sofosbuvir. The active site of hHint1 comprises an ensemble of strictly conserved histidines, including nucleophilic His112. To structurally investigate the mechanism of hHint1 catalysis, we have designed and prepared nucleoside thiophosphoramidate substrates that are able to capture the transiently formed nucleotidylated-His112 intermediate (E*) using time-dependent crystallography. Utilizing a catalytically inactive hHint1 His112Asn enzyme variant and wild-type enzyme, the enzyme-substrate (ES1) and product (EP2) complexes were also cocrystallized, respectively, thus providing a structural map of the reaction trajectory. On the basis of these observations and the mechanistic necessity of proton transfers, proton inventory studies were carried out. Although we cannot completely exclude the possibility of more than one proton in flight, the results of these studies were consistent with the transfer of a single proton during the formation of the intermediate. Interestingly, structural analysis revealed that the critical proton transfers required for intermediate formation and hydrolysis may be mediated by a conserved active site water channel. Taken together, our results provide mechanistic insights underpinning histidine nucleophilic catalysis in general and hHint1 catalysis, in particular, thus aiding the design of future proTides and the elucidation of the natural function of the Hint family of enzymes.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28691797     DOI: 10.1021/acs.biochem.7b00148

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  5 in total

Review 1.  Current and future use of nucleo(s)tide prodrugs in the treatment of hepatitis C virus infection.

Authors:  Cyril B Dousson
Journal:  Antivir Chem Chemother       Date:  2018 Jan-Dec

Review 2.  Phosphoramidates and phosphonamidates (ProTides) with antiviral activity.

Authors:  Magdalena Slusarczyk; Michaela Serpi; Fabrizio Pertusati
Journal:  Antivir Chem Chemother       Date:  2018 Jan-Dec

3.  Tissue-Specific Proteomics Analysis of Anti-COVID-19 Nucleoside and Nucleotide Prodrug-Activating Enzymes Provides Insights into the Optimization of Prodrug Design and Pharmacotherapy Strategy.

Authors:  Jiapeng Li; Shuhan Liu; Jian Shi; Xinwen Wang; Yanling Xue; Hao-Jie Zhu
Journal:  ACS Pharmacol Transl Sci       Date:  2021-04-01

4.  Histidine-Triad Hydrolases Provide Resistance to Peptide-Nucleotide Antibiotics.

Authors:  Eldar Yagmurov; Darya Tsibulskaya; Alexey Livenskyi; Marina Serebryakova; Yury I Wolf; Sergei Borukhov; Konstantin Severinov; Svetlana Dubiley
Journal:  mBio       Date:  2020-04-07       Impact factor: 7.867

5.  ATI-2173, a Novel Liver-Targeted Non-Chain-Terminating Nucleotide for Hepatitis B Virus Cure Regimens.

Authors:  Katherine E Squires; Douglas L Mayers; Gregory R Bluemling; Alexander A Kolykhalov; David B Guthrie; Prabhakar Reddy; Debbie G Mitchell; Manohar T Saindane; Zachary M Sticher; Vindhya Edpuganti; Abel De La Rosa
Journal:  Antimicrob Agents Chemother       Date:  2020-08-20       Impact factor: 5.191

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.